|
End-of-day quote
Nasdaq Stockholm
21/10/2026
|
5-day change | 1st Jan Change | ||
| 3.225 SEK | +1.10% |
|
+2.87% | -29.89% |
| 10-13 | Active Biotech completes first safety cohort in study of tasquinimod | FW |
| 10-13 | Active Biotech completes first safety cohort in myelofibrosis study | FW |
Company Valuation: Active Biotech AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 275.5 | 254.8 | 165.1 | 115.9 | 121.3 | 90.81 | - | - |
| Change | - | -7.51% | -35.2% | -29.8% | 4.6% | -25.11% | - | - |
| Enterprise Value (EV) | 223.1 | 254.8 | 128.9 | 88.53 | 121.3 | 90.81 | 90.81 | 90.81 |
| Change | - | 14.2% | -49.4% | -31.34% | 36.97% | -25.11% | 0% | 0% |
| P/E | - | - | - | - | - | - | - | - |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | -5.54x |
| EV / Revenue | - | - | - | - | - | - | - | -5.54x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -2.61x | 5.47x | 1.81x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -2.74x | 4.99x | 1.75x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | - | - | - | - | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | -16.4 |
| EBITDA 1 | -48.5 | -56.4 | -44.8 | -38.2 | -36 | -34.8 | 16.6 | 50.2 |
| EBIT 1 | -49.8 | -57.9 | -46.5 | -39.8 | -37.6 | -33.2 | 18.2 | 51.8 |
| Net income 1 | -49.8 | -58.4 | -45.8 | -39.4 | -37.32 | -33.2 | 18.2 | 51.8 |
| Net Debt | -52.37 | - | -36.2 | -27.4 | - | - | - | - |
| Reference price 2 | 126.400 | 96.200 | 45.650 | 10.880 | 4.600 | 3.445 | 3.445 | 3.445 |
| Nbr of stocks (in thousands) | 2,180 | 2,649 | 3,617 | 10,655 | 26,361 | 26,361 | - | - |
| Announcement Date | 25/03/22 | 09/02/23 | 08/02/24 | 13/02/25 | 01/04/26 | - | - | - |
1SEK in Million2
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 9.15M | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 7.93x | 26.43x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 32.66x | 5.97x | 20.09x | -.--% | 23.67B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| Average | 26.77x | 26.45x | 15.70x | 0.32% | 38.31B | |
| Weighted average by Cap. | 26.72x | 25.32x | 15.93x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ACTI Stock
- Valuation Active Biotech AB
Select your edition
All financial news and data tailored to specific country editions
